Though soluble PD-L1 has been proven to be a good predictor of the recurrence and survival of HCC [132], recent studies found that exosomal PD-L1, but not other forms of extracellular PD-L1, could be used to predict the prognosis or response to immunotherapy in various cancer types [133]. The gene discussed is CD274; the disease is hepatocellular carcinoma.